Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spine implants worldwide. It offers products for thoracolumbar procedures, including Streamline TL Spinal Fixation system, a system for degenerative and complex spine procedures; and Streamline MIS Spinal Fixation system, a range of implants and instruments used via a percutaneous or mini-open approach; and interbody fusion devices, as well as products for cervical procedures, such as CervAlign ACP system, a comprehensive anterior cervical plate system; Fortilink-C IBF system, a cervical interbody fusion device that utilizes TETRAfuse 3D technology; and Streamline OCT system, a range of implants used in the occipito-cervico-thoracic posterior spine. The company also provides motion preservation systems comprising Coflex Interlaminar Stabilization device for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; HPS 2.0 Universal Fixation system, a pedicle screw system used for posterior stabilization of the thoracolumbar spine; SImmetry SI Joint Fusion system, a minimally invasive surgical implant system to decrease opioid use, pain, and disability. In addition, it develops Augmented Reality and Artificial Intelligence digital surgery platform to enable digital spine surgery. The company markets its products through independent spine and biomaterial distributors to hospitals, ambulatory surgery centers, and healthcare providers, as well as through direct sales force. It has a collaboration with Inteneural Networks for clinical neurosciences; and strategic agreement with Exactech, Inc. for the development and supply of biologic bone substitutes. The company was incorporated in 1997 and is headquartered in Deerfield, Illinois.
IPO Year:
Exchange: NASDAQ
Website: surgalign.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/28/2021 | $1.50 | Buy → Hold | Craig Hallum |
15-12G - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)
EFFECT - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)
EFFECT - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)
EFFECT - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)
S-8 POS - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)
S-8 POS - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)
S-8 POS - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)
POS AM - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)
POS AM - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)
POS AM - SURGALIGN HOLDINGS, INC. (0001760173) (Filer)
4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)
4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)
4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)
4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)
4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)
4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)
4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)
4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)
4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)
4 - SURGALIGN HOLDINGS, INC. (0001760173) (Issuer)
DEERFIELD, Ill., June 23, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, announced today that on June 22, 2023, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"). Nasdaq has determined that due to the Company's voluntary petition for relief under chapter 11 of the U.S. Bankruptcy Code, the Company's securities will be delisted from The Nasdaq Stock Market. The Company does not intend to appeal Nasdaq's determination. As previously announced, Surgalign entered into an asset purchase agreement to
DEERFIELD, Ill., June 20, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) ("Surgalign" or the "Company") a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced that the Company has entered into an asset purchase agreement (the "Asset Purchase Agreement") to sell substantially all of its U.S. hardware and biomaterials assets and the equity interests in non-Debtor entities related to the Debtors' hardware business outside of the U.S. to Xtant Medical Holdings, Inc. ("Xtant") for $5.0 million. The sale will be effectuated through the chapter 11 proceedings initiated by the Company and certain o
Company to showcase its upgraded HOLO Portal™ Surgical Guidance System and key products in its hardware spine and biologics portfolio DEERFIELD, Ill., May 23, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, announced today that it will be exhibiting at ISASS 2023 – the 23rd Annual Conference – sponsored by the International Society for Spine Surgery ("ISASS") and Medical Education Resources. This three-day event will take place June 1-3, 2023 at the Marriott Marquis in San Francisco, CA. The International Society for the Advancement of Spine Surgery i
DEERFIELD, Ill., May 11, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced financial results for its 2023 first quarter ended March 31, 2023. 2023 First Quarter and Subsequent Corporate Highlights: Launch of HOLO™ AI Insights for Spine Imaging; collaboration with Dr. Alexander Vaccaro, Dr. Pierce Nunley and Spine Institute of Louisiana, and leading neuro and orthopedic spine surgeons and San Diego Spine Foundation.Launch of HOLO AI Insights for Neurovascular Research; collaboration with Dr. Brian Jankowitz, a fellowship trained cerebrov
DEERFIELD, Ill., May 08, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, is proud to announce today, the release of HOLO™ AI Insights for use in neurovascular research. HOLO AI Insights, initially launched in March 2023 for spine imaging, enables customers, partners, and clinical researchers to take advantage of the Company's HOLO artificial intelligence (AI) portfolio through a secure, highly scalable cloud platform for automated analysis of medical images. HOLO AI, Surgalign's portfolio of AI technology, utilizes convolutional neural network technolo
DEERFIELD, Ill., May 04, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced its plans to release financial results for its first quarter 2023 after the close of trading on May 11, 2023. Surgalign will host a conference call and audio webcast at 4:30 p.m. ET the same day. The conference call can be accessed by dialing (888) 437-3179 (U.S.) or 862-298-0702 (International). The webcast can be accessed through the investor relations section of Surgalign's website at www.surgalign.com/investors. A replay of the conference call will be available
DEERFIELD, Ill., May 03, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, is pleased to announce new collaborative alliances with Dr. Pierce Nunley and the Spine Institute of Louisiana, a prestigious medical facility and one of the top 20 patient-rated U.S. hospitals for best overall care, and Dr. Alexander Vaccaro, an advisor to Surgalign and one of the top-ranked spine experts in the world. These new collaborations seek to advance Surgalign's recently introduced HOLO™ AI Insights solution for lumbar spine imaging, which was launched in March 2023, and
DEERFIELD, Ill., April 13, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, announced today that on April 10, 2023, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it is no longer in compliance with the $10 million minimum stockholders' equity requirement for continued listing on the NASDAQ Global Select Market under Nasdaq Listing Rule 5450(b)(1)(A). The notification letter further indicated that the Company does not meet alternative standards set forth in
DEERFIELD, Ill., March 30, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today reported operating results for its fourth quarter and full year 2022 ending December 31, 2022. 2022 Fourth Quarter and Subsequent 2023 Corporate Highlights: Expansion of HOLO Portal™ into Virginia and Texas; over 30 cases performed since commercial launchLaunched HOLO™ AI Insights, part of the HOLO AI portfolio, to provide powerful population analytics of spine MRI imagesHOLO Portal receives 2022 Best New Technology Award from Orthopedics This Week100th case completed u
DEERFIELD, Ill., March 21, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced its plans to release financial results for its fourth quarter and full year 2022 after the close of trading on March 30, 2023. Surgalign will host a conference call and audio webcast at 4:30 p.m. ET the same day. The conference call can be accessed by dialing (866) 604-1616 (U.S.) or 201-689-8043 (International). The webcast can be accessed through the investor relations section of Surgalign's website at www.surgalign.com/investors. A replay of the conference cal
Craig Hallum downgraded Surgalign Holdings from Buy to Hold and set a new price target of $1.50
BTIG Research initiated coverage of Surgalign Holdings with a rating of Buy and set a new price target of $4.00
BTIG Research initiated coverage of Surgalign with a rating of Buy
Piper Sandler initiated coverage of Surgalign Holdings with a rating of Overweight and set a new price target of $4.00
DEERFIELD, Ill., May 04, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced its plans to release financial results for its first quarter 2023 after the close of trading on May 11, 2023. Surgalign will host a conference call and audio webcast at 4:30 p.m. ET the same day. The conference call can be accessed by dialing (888) 437-3179 (U.S.) or 862-298-0702 (International). The webcast can be accessed through the investor relations section of Surgalign's website at www.surgalign.com/investors. A replay of the conference call will be available
Expands Xtant's Product Offering with the Leading PMA-Approved Intralaminar Stabilization Device Strengthens Surgalign's Balance Sheet as it Embarks on its Digital Health Strategy BELGRADE, Mont. and DEERFIELD, Ill., March 01, 2023 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, and Surgalign Holdings, Inc., (NASDAQ:SRGA), a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced the completion of a transaction between the companies. On February 28, 2023, Xtant Medical and Surgalign entered
DEERFIELD, Ill., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced financial results for its 2022 third quarter ended September 30, 2022. 2022 Third Quarter Corporate Highlights: Two new clinical sites in Ohio utilize the HOLO PortalTM surgical guidance system.FDA 510(k) clearance of the Cortera™ Spinal Fixation System, the first organically designed product by Surgalign.Expansion of the Fortilink® product portfolio with TiPlus™ technology products.Settlements with Resolve Surgical Technologies and RTI Surgical, Inc., and with
DEERFIELD, Ill., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced its plans to release financial results for its third quarter ended September 30, 2022 after the close of trading on November 2, 2022. Surgalign will host a conference call and audio webcast at 4:30 p.m. ET the same day. The conference call can be accessed by dialing (866) 604-1616 (U.S.) or 201-689-8043 (International). The webcast can be accessed through the investor relations section of Surgalign's website at www.surgalign.com/investors. A replay of the conferen
DEERFIELD, Ill., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced financial results for its 2022 second quarter ended June 30, 2022. 2022 Second Quarter Key Highlights and Subsequent Events: First successful surgical procedures utilizing the HOLO Portal™ Surgical Guidance System in Indiana and further expansion in Ohio with more sites in the pipeline.Launch of the Surgalign® Patient Access Program: formed strategic partnership with PRIA Healthcare to support Program and improve patient healthcare coverage.Relaunch
DEERFIELD, Ill., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced its plans to release financial results for its second quarter ended June 30, 2022 after the close of trading on August 9, 2022. Surgalign will host a conference call and audio webcast at 4:30 p.m. ET the same day. The conference call can be accessed by dialing (888) 645-4404 (U.S.) or (404) 267-0371 (International). The webcast can be accessed through the investor section of Surgalign's website at www.surgalign.com/investors. A replay of the conference call will b
DEERFIELD, Ill., April 26, 2022 (GLOBE NEWSWIRE) -- Surgalign Spine Technologies, (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care through the evolution of digital surgery, today announced it plans to release financial results from the first quarter 2022 after the close of trading on May 10th, 2022. Surgalign will host a conference call and audio webcast at 4:30 p.m. ET the same day. The conference call can be accessed by dialing (866) 604-1616 (U.S.) or (201) 689-8043 (International). The webcast can be accessed through the investor section of Surgalign's website at surgalign.com/investors/. A replay of the conference call will be available on S
DEERFIELD, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced it plans to release financial results from the fourth quarter and full year 2021 after the close of trading on March 15, 2022. Surgalign will host a conference call and audio webcast at 4:30 p.m. ET the same day. The conference call can be accessed by dialing (866) 604-1616 (U.S.) or (201) 689-8043 (International), using conference ID 13726530. The webcast can be accessed through the investor section of Surgalign's website at surgalign.com/investors/. A replay of
DEERFIELD, Ill., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Surgalign Spine Technologies, (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care through the evolution of digital surgery, today announced it plans to release financial results from the third quarter 2021 after the close of trading on November 9, 2021. Surgalign will host a conference call and audio webcast at 4:30 p.m. ET the same day. The conference call can be accessed by dialing (866) 682-6100 (U.S.) or (862) 298-0702 (International), using conference ID 13724073. The webcast can be accessed through the investor section of Surgalign's website at surgalign.com/investors/. A replay of the confere
DEERFIELD, Ill., July 23, 2021 (GLOBE NEWSWIRE) -- Surgalign Spine Technologies, (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced it plans to release financial results from the second quarter 2021 before the open of trading on Friday August 6, 2021. Surgalign will host a conference call and audio webcast at 9:00 a.m. ET the same day. The conference call can be accessed by dialing (866) 604-1616 (U.S.) or (201) 689-8043 (International), using conference ID 13721429. The webcast can be accessed through the investor section of Surgalign's website at surgalign.com/investors/. A replay of
DEERFIELD, Ill., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced the appointment of Paolo Amoruso as its new General Counsel and Corporate Secretary, effective August 1, 2022. He previously served as Interim General Counsel of Surgalign, having joined the Company in April 2022. Commenting on today's appointment, Terry Rich, President and Chief Executive Officer of Surgalign stated, "Paolo has been an invaluable member of our team since taking on the role of Interim General Counsel just a few months ago. He has quickly immersed
DEERFIELD, Ill., March 07, 2022 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (NASDAQ:SRGA) ("Surgalign"), a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced the appointment of David Lyle, as Chief Financial Officer, effective immediately. "David brings a wealth of experience in helping to guide the growth of technologies to Surgalign at an important and exciting inflection point of the company's evolution," said Terry Rich, Surgalign's president and chief executive officer. "David is joining Surgalign at a critical time as we transition to the early commercial stage of our HOLO AI technology platform, w
BEDFORD, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that its Board of Directors has appointed Sheryl Conley as independent director, effective October 28, 2021. Sheryl Conley joins the Anika Board of Directors with over 35 years of orthopedic and healthcare industry experience, most recently as President and CEO of OrthoWorx, Inc., and previously as Group President, Americas and Global Brand Management, and Chief Marketing Officer for Zimmer, Inc. Ms. Conley brings extensive orthopedic medical device industry knowledge with a focus on global brand management
DEERFIELD, Ill., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc. (NASDAQ:SRGA), a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced that Sheryl Conley will be appointed to the role of non-executive Chair of the Surgalign Board of Directors, effective September 14, 2021. Conley was appointed to the Board as a director on May 4, 2021, during the Annual Meeting of Stockholders of Surgalign Holdings, Inc. She has more than 35 years of expertise and broad-based executive leadership experience in the orthopedic medical device industry running full P&L business segments, global brand management, ma
DEERFIELD, Ill., April 14, 2021 (GLOBE NEWSWIRE) -- Surgalign Spine Technologies, (NASDAQ:SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced the appointment of Marc Mackey as Executive Vice President, Digital Surgery, effective immediately. In the newly created position reporting directly to Surgalign CEO Terry Rich, Mr. Mackey will lead the company's efforts to redefine and lead digital surgery. "As an organization, we are highly focused on harnessing technology to make digital surgery a reality that delivers better outcomes to patients, surgeons and medical centers," said Rich. "Our vision go
SC 13G/A - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)
SC 13G - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)
SC 13D - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)
SC 13D/A - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)
SC 13G/A - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)
SC 13G/A - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)
SC 13G/A - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)
SC 13D/A - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)
SC 13G/A - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)
SC 13G - SURGALIGN HOLDINGS, INC. (0001760173) (Subject)